CRVO Quote, Financials, Valuation and Earnings

Curis, Inc. has a net margin of -92957.47% compared to CervoMed, Inc.'s net margin of -243.36%. CervoMed, Inc.'s return on equity of -88.99% beat Curis, Inc.'s return on equity of -461.34%.

CervoMed, Inc. has a consensus price target of $22.14, signalling upside risk potential of 434.85%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 2445.92%. Given that Curis, Inc. has higher upside potential than CervoMed, Inc., analysts believe Curis, Inc. is more attractive than CervoMed, Inc..

CervoMed, Inc. has a beta of -0.673, which suggesting that the stock is 167.319% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.148, suggesting its more volatile than the S&P 500 by 214.753%.

CervoMed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.

CervoMed, Inc. quarterly revenues are $8.7K, which are smaller than Curis, Inc. quarterly revenues of $1.1M. CervoMed, Inc.'s net income of -$8.1M is lower than Curis, Inc.'s net income of $19.4M. Notably, CervoMed, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed, Inc. is 9.62x versus 0.77x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Halozyme Therapeutics, Inc. has a net margin of -92957.47% compared to CervoMed, Inc.'s net margin of -31.34%. CervoMed, Inc.'s return on equity of -88.99% beat Halozyme Therapeutics, Inc.'s return on equity of 91.5%.

CervoMed, Inc. has a consensus price target of $22.14, signalling upside risk potential of 434.85%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $84.89 which suggests that it could grow by 31.03%. Given that CervoMed, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe CervoMed, Inc. is more attractive than Halozyme Therapeutics, Inc..

CervoMed, Inc. has a beta of -0.673, which suggesting that the stock is 167.319% less volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 1.031, suggesting its more volatile than the S&P 500 by 3.116%.

CervoMed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed, Inc. pays -- of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend.

CervoMed, Inc. quarterly revenues are $8.7K, which are smaller than Halozyme Therapeutics, Inc. quarterly revenues of $451.8M. CervoMed, Inc.'s net income of -$8.1M is higher than Halozyme Therapeutics, Inc.'s net income of -$141.6M. Notably, CervoMed, Inc.'s price-to-earnings ratio is -- while Halozyme Therapeutics, Inc.'s PE ratio is 25.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed, Inc. is 9.62x versus 5.59x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -92957.47% compared to CervoMed, Inc.'s net margin of -417.92%. CervoMed, Inc.'s return on equity of -88.99% beat Plus Therapeutics, Inc.'s return on equity of --.

CervoMed, Inc. has a consensus price target of $22.14, signalling upside risk potential of 434.85%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than CervoMed, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than CervoMed, Inc..

CervoMed, Inc. has a beta of -0.673, which suggesting that the stock is 167.319% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.

CervoMed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

CervoMed, Inc. quarterly revenues are $8.7K, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. CervoMed, Inc.'s net income of -$8.1M is lower than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, CervoMed, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed, Inc. is 9.62x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Windtree Therapeutics, Inc. has a net margin of -92957.47% compared to CervoMed, Inc.'s net margin of --. CervoMed, Inc.'s return on equity of -88.99% beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.

CervoMed, Inc. has a consensus price target of $22.14, signalling upside risk potential of 434.85%. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 38734.95%. Given that Windtree Therapeutics, Inc. has higher upside potential than CervoMed, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than CervoMed, Inc..

CervoMed, Inc. has a beta of -0.673, which suggesting that the stock is 167.319% less volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.672, suggesting its less volatile than the S&P 500 by 32.828%.

CervoMed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed, Inc. pays -- of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CervoMed, Inc. quarterly revenues are $8.7K, which are larger than Windtree Therapeutics, Inc. quarterly revenues of --. CervoMed, Inc.'s net income of -$8.1M is higher than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, CervoMed, Inc.'s price-to-earnings ratio is -- while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed, Inc. is 9.62x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.